Related references
Note: Only part of the references are listed.Affibody Molecules as Targeting Vectors for PET Imaging
Vladimir Tolmachev et al.
CANCERS (2020)
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo
Tiziano Ongaro et al.
Oncotarget (2020)
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
Jean-Frederic Colombel et al.
JOURNAL OF CROHNS & COLITIS (2020)
Tenascin-C Produced by Intestinal Myofibroblasts Promotes Colitis-associated Cancer Development Through Angiogenesis
Takafumi Kawamura et al.
INFLAMMATORY BOWEL DISEASES (2019)
F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET Guided Translational Approach
Stefan T. G. Bruijnen et al.
MOLECULAR PHARMACEUTICS (2019)
Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis
Amanda C. Freise et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance
Cornelius Cilliers et al.
MOLECULAR PHARMACEUTICS (2017)
Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease
Sufeng Zhang et al.
NANO TODAY (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
The extracellular matrix in IBD: a dynamic mediator of inflammation
Aaron C. Petrey et al.
CURRENT OPINION IN GASTROENTEROLOGY (2017)
Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging
Liang Zhang et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
Franziska Bootz et al.
DRUG DISCOVERY TODAY (2016)
Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis
Franziska Bootz et al.
INFLAMMATORY BOWEL DISEASES (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Mechanistic and quantitative insight into cell surface targeted molecular imaging agent design
Liang Zhang et al.
SCIENTIFIC REPORTS (2016)
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M. L. Zegers et al.
CLINICAL CANCER RESEARCH (2015)
Drug delivery strategies in the therapy of inflammatory bowel disease
Christian Lautenschlaeger et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
PDGF and TGF-β promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice
M. S. Islam et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Oral Delivery of IL-27 Recombinant Bacteria Attenuates Immune Colitis in Mice
Miranda L. Hanson et al.
GASTROENTEROLOGY (2014)
Multichannel Imaging to Quantify Four Classes of Pharmacokinetic Distribution in Tumors
Sumit Bhatnagar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Diagnostic performance of Fluorine-18-Fluorodeoxy-glucose positron emission tomography in patients with chronic inflammatory bowel disease: A systematic review and a meta-analysis
Giorgio Treglia et al.
JOURNAL OF CROHNS & COLITIS (2013)
Translational 18F-FDG PET/CT Imaging to Monitor Lesion Activity in Intestinal Inflammation
Dominik Bettenworth et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse
Fabia Doll et al.
ARTHRITIS RESEARCH & THERAPY (2013)
A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies
Sabrina Oliveira et al.
EJNMMI RESEARCH (2012)
Exploration of target molecules for molecular imaging of inflammatory bowel disease
Kei Higashikawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Emerging immunological targets in inflammatory bowel disease
Giovanni Monteleone et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
A Proteomic Approach for the Identification of Vascular Markers of Liver Metastasis
Beatrice Borgia et al.
CANCER RESEARCH (2010)
Near-infrared fluorescence: application to in vivo molecular imaging
Scott A. Hilderbrand et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
An improved yeast transformation method for the generation of very large human antibody libraries
Lorenzo Benatuil et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
Kathrin Schwager et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis
Paolo Conrotto et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Molecular imaging in drug development
Juergen K. Willmann et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The extra-domain a of fibronectin is a vascular marker of solid tumors and Metastases
Jascha-N. Rybak et al.
CANCER RESEARCH (2007)
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
Simon S. Brack et al.
CLINICAL CANCER RESEARCH (2006)
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature
JN Rybak et al.
NATURE METHODS (2005)
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
DA Rizzieri et al.
BLOOD (2004)
Phase II trial of murine I-131-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Serum tenascin-C is an indicator of inflammatory bowel disease activity
S Riedl et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2001)
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2000)
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
ET Boder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
